PTCL is characterized by highly heterogeneous clinical manifestations.[48] To further determine the clinical and pathological relevance of SLC3A2 and the suppression of ASS1 across different PTCL subtypes, we performed immunofluorescence to detect SLC3A2 and ASS1 expression in a tissue microarray containing 35 PTCL and eight reactive lymphoid hyperplasia (RLH) samples (Figure 3N). Here, SLC3A2 is linked to mature T-cell and NK-cell non-Hodgkin lymphoma.